Coronavirus company news summary - UofL receives $8.5m in funding to develop and test Covid-19 nasal spray
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – UofL receives $8.5m in funding to develop and test Covid-19 nasal spray

10 Dec 2020

10 December

The University of Louisville (UofL) has received $8.5m in funding from the US Department of Defense (DoD) to develop and test a nasal spray in phase 1 clinical trial to evaluate its ability to prevent viral respiratory infections such as Covid-19 using Q-Griffithsin, a drug compound developed by UofL.

The US DoD announced that it had chosen certain sites at Fort Bragg, Joint Base Lewis-McChord and Keesler Air Force Base to distribute Covid-19 vaccines among military personnel. Those and other sites will receive Pentagon’s first allotment of approximately 44,000 doses of the Pfizer vaccine for military personnel, after being granted emergency use authorisation (EUA) from the US Food and Drug Administration (FDA).

South Korea’s defence ministry announced that it would be dispatching more than 300 military officers to help the government tackle the virus resurgence in the country. Approximately 362 officers from the Army’s special warfare command will report to public health centres in Seoul to help combat the antivirus work, which will include data management and contact tracing tasks.